Brief: Adaptimmune Therapeutics PLC Lete-Cel Achieves Primary Endpoint In Pivotal Trial
13/11/2024 14:14
Nov 13 (Reuters) - Adaptimmune Therapeutics PLC
ADAP.O :
* ADAPTIMMUNE THERAPEUTICS PLC: LETE-CEL ACHIEVES PRIMARY
ENDPOINT IN PIVOTAL TRIAL
Source text: ID:n0001558370-24-015446
Further company coverage: ADAP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview